SCHEMBL7920680

SCHEMBL7920680

Cc1ccc2c(c1)C(C)NO2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.37
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
HTR2C P28335 4/20 0.35
ALDH1A1 P00352 2/20 0.34
MAPT P10636 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HTR2B P41595 2/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
HTR1A P08908 1/20 0.34
SLC6A2 P23975 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
ADRA2A P08913 1/20 0.34
MMP12 P39900 1/20 0.33
KMT2A Q03164 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7923004 0.84 ALDH1A1 (0.37) GAABRD4CREBBPCHRNB2CHRNA4
SCHEMBL8313667 0.78 GAA (0.39) GAABRD4CREBBPCHRNB2CHRNA4
SCHEMBL13999538 0.71 GAA (0.46) GAABRD4CREBBPALDH1A1HSD17B10
SCHEMBL19426125 0.69 DRD2 (0.39) HSD17B10ADRA2AKDM4E
SCHEMBL14538282 0.67 ALDH1A1 (0.36) GAACHRNB2CHRNA4HTR2CALDH1A1
SCHEMBL16199826 0.67 ALDH1A1 (0.36) GAACHRNB2CHRNA4HTR2CALDH1A1
SCHEMBL8191875 0.67 HTR2C (0.37) CHRNB2CHRNA4HTR2CMAPTHSD17B10
SCHEMBL7926259 0.65 CHRNA7 (0.34) CYP1A2CYP2A6
SCHEMBL7923045 0.65 CYP1A2 (0.32) CYP1A2
SCHEMBL17193797 0.65 GAA (0.38) GAABRD4CREBBPCHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 EP disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB GAA 1084/4885BRD4 1145/4885CREBBP 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.